Estrogen Effects on Bone Health in Postmenopausal Women

Oestrogen plays a pivotal role in maintaining bone homeostasis through direct effects on bone cells and modulation of the bone microenvironment. In premenopausal women, oestrogen suppresses osteoclastogenesis, promotes osteoblast survival and regulates osteocyte signalling, thus preserving bone density and microarchitecture. Following menopause, the sharp decline in circulating oestrogen disrupts the equilibrium between bone formation and resorption, leading to accelerated bone turnover, loss of trabecular connectivity and increased cortical porosity. The ensuing imbalance predisposes postmenopausal women to reduced bone strength and heightened fracture risk. Beyond skeletal cells, oestrogen deficiency also influences immune and inflammatory pathways, augmenting pro-osteoclastogenic cytokine production. Recent work has further elucidated the mechanobiological consequences of oestrogen loss, including altered mechanotransduction in osteocytes and changes in primary cilium dynamics that exacerbate bone loss. Clinically, menopausal hormone therapy offers protection against fracture but must be balanced against potential risks. As the global population ages, understanding the multifaceted effects of oestrogen on bone health remains vital for improving prevention and treatment strategies.

Research from Nature Portfolio

Two key mechanistic studies have deepened understanding of how oestrogen deficiency precipitates bone loss. One investigation revealed that oestrogen withdrawal impairs αvβ3 integrin–mediated focal adhesion formation in osteocytes, disrupting mechanotransduction and skewing the RANKL/OPG ratio in favour of osteoclastogenesis. This work highlights a novel cell‐adhesion–based mechanism contributing to postmenopausal osteoporosis. A complementary study demonstrated that oestrogen withdrawal leads to elongation of the primary cilium in osteocytes, activating Hedgehog signalling and further amplifying pro-osteoclastogenic paracrine cues. Linking cytoskeletal disorganisation to ciliary dynamics, this research uncovers how structural changes at the cellular level translate into increased bone resorption. Together, these studies establish new molecular targets that may inform the development of therapies aimed at preserving bone integrity in oestrogen‐deficient states.

Estrogen Effects on Bone Health in Postmenopausal Women publication trend

The graph below shows the total number of articles in estrogen effects on bone health in postmenopausal women across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoclast: A bone‐resorbing cell responsible for degradation of mineralised bone matrix.

Osteoblast: A bone‐forming cell that synthesises and mineralises new bone matrix.

Osteocyte: A mature bone cell embedded in mineralised matrix that senses mechanical load and regulates remodelling.

RANKL/OPG ratio: The balance between receptor activator of nuclear factor κB ligand (pro-resorptive) and osteoprotegerin (decoy receptor), determining osteoclast activity.

Mechanotransduction: The process by which cells convert mechanical stimuli into biochemical signals.

Primary cilium: A solitary cellular organelle that organises signalling pathways, including Hedgehog, in osteocytes.

Integrin αvβ3: A cell‐adhesion receptor mediating interactions between osteocytes and the extracellular matrix, essential for mechanosensation.

References

1. Insights and implications of sexual dimorphism in osteoporosis. Bone Research (2024).
2. Update on Menopausal Hormone Therapy for Fracture Prevention. Current Osteoporosis Reports (2019).
3. Estrogen deficiency impairs integrin αvβ3-mediated mechanosensation by osteocytes and alters osteoclastogenic paracrine signalling. Scientific Reports (2019).
4. Estrogen withdrawal alters cytoskeletal and primary ciliary dynamics resulting in increased Hedgehog and osteoclastogenic paracrine signalling in osteocytes. Scientific Reports (2021).
5. A Novel 3D Osteoblast and Osteocyte Model Revealing Changes in Mineralization and Pro-osteoclastogenic Paracrine Signaling During Estrogen Deficiency. Frontiers in Bioengineering and Biotechnology (2020).